Hookipa Pharma Inc

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

NEW YORK and VIENNA, Austria, Aug. 05, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that pre-clinical data on its replicating Lymphocytic choriomeningitis (LCMV) arenaviral-based immunotherapeutic has been published in the peer-reviewed journal, Nature Communications. The data demonstrate that HOOKIPA's LCMV-based vector, designed to target melanoma, modulated the tumor microenvironment and induced potent, tumor antigen-specific T cell responses, resulting in tumor regression and tumor cures in a pre-clinical setting. The publication is available online.

Pre-clinical data on HOOKIPA's arenaviral immunotherapeutic in melanoma published in Nature Communications

NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate and present at the following upcoming virtual investor conferences:

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June

Aclaris Therapeutics

CureVac B.V

Jiuzi Holdings

Ra Medical Systems Inc

The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.

RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday

Hookipa Pharma Inc (NASDAQ: HOOK) reported positive Phase 1 data from its ongoing Phase 1/2 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive (HPV16+) cancers. Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer Settings

NEW YORK and VIENNA, Austria, June 07, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported positive Phase 1 data from its ongoing Phase 1/2 study (NCT04180215) of HB-200 for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers. Data presented as an oral presentation (abstract #2502) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting showed outstanding T cell responses, preliminary efficacy as a monotherapy in heavily pretreated patients who progressed on standard of care, including checkpoint inhibitors, and favorable tolerability. The company also announced translational data suggesting a relationship between T cell response and potential clinical efficacy. The company will host an investor event today at 6:30pm EDT.

HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

HOOKIPA Pharma Inc. (HOOK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

HOOKIPA Pharma Inc. (HOOK) Soars 7.9%: Is Further Upside Left in the Stock?

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 0.00% and 38.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Tops Revenue Estimates

Shares of HOOKIPA Pharma (NASDAQ:HOOK) fell 6.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 23.26% year over year to ($0.53), which were in line with the estimate of ($0.53).

HOOKIPA Pharma: Q1 Earnings Insights

NEW YORK and VIENNA, Austria, May 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2021.

HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights

HOOKIPA (HOOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for HOOKIPA (HOOK) This Earnings Season?

NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021.

HOOKIPA Pharma to Present at Kempen Life Science Conference

NEW YORK and VIENNA, Austria, April 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive preliminary Phase 1 immunogenicity data for its lead oncology candidates, HB-201 and HB-202, to treat Human Papillomavirus 16-positive (HPV16+) cancers. The results are from an ongoing Phase 1/2 study (NCT04180215) currently investigating HB-201 as a single-vector therapy and HB-201 and HB-202 as an alternating two-vector therapy for the treatment of advanced metastatic HPV16+ cancers. The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2020 Results - Earnings Call Transcript

Shares of HOOKIPA Pharma (NASDAQ:HOOK) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 15.00% over the past year to ($0.46), which beat the estimate of ($0.58).

HOOKIPA Pharma: Q4 Earnings Insights

NEW YORK and VIENNA, Austria, March 18, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2020.

HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook

HOOKIPA Pharma (HOOK) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

HOOKIPA Pharma (HOOK) in Focus: Stock Moves 8.4% Higher

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease/oncology pipeline of six therapeutics. including three in clinical trials including HB-101 for CMV (Phase 2), HB-201 for HPV16+ Cancer (Phase 1/2), and HB-201/-202 for HPV16+ Cancer (Phase 1).

Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside

NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,910,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the public offering price of each share of Series A preferred stock is $11,750 (each share of Series A preferred stock is convertible into 1,000 shares of common stock). The gross proceeds to HOOKIPA from this offering are expected to be approximately $80.9 million before deducting underwriting discounts and commissions and other offering expenses, which includes the exercise in full of the underwriters' option to purchase 510,000 additional shares. All of the securities in the Offering were sold by HOOKIPA.

HOOKIPA Pharma Announces Closing of Public Offering of $80.9 Million of Common Stock and Preferred Stock, Including Full Exercise of Underwriters' Option

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the public offering price of each share of Series A preferred stock is $11,750 (each share of Series A preferred stock is convertible into 1,000 shares of common stock). HOOKIPA has granted the underwriters a 30-day option to purchase up to an additional 510,000 shares of its common stock at the public offering price of the common stock, less underwriting discounts and commissions. The gross proceeds to HOOKIPA from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the Offering are to be sold by HOOKIPA. The offering is expected to close on December 11, 2020, subject to customary closing conditions.

HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred Stock

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering (the “Offering”). HOOKIPA also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the Offering, including the shares of common stock underlying the Series A convertible preferred stock. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. All of the securities in the Offering are to be sold by HOOKIPA.

HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred Stock

HOOKIPA (HOOK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

HOOKIPA (HOOK) Surges: Stock Moves 8.6% Higher

Gamida Cell Ltd

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida Cell is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases.

Why Gamida, Scpharmaceuticals And Hookipa Are Moving Today

NEW YORK and VIENNA, Austria, Dec. 07, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive interim Phase 1 data on HB-201, its replicating monotherapy for the treatment of HPV16+ cancers. The results are from the initial dose escalation cohorts of an ongoing Phase 1/2 clinical trial (NCT04180215) evaluating HB- 201 as therapy for patients with advanced HPV16+ metastatic cancers. HOOKIPA will host a conference call and live audio webcast today at 8:30am EST.

HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability

NEW YORK and VIENNA, Austria, Nov. 30, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive interim efficacy results, as well as additional safety and immunogenicity data, for its prophylactic Cytomegalovirus (CMV) vaccine candidate HB-101. HB-101, a non-replicating arenavirus vaccine, is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in individuals receiving a kidney transplant from a living donor. HOOKIPA will host a conference call and live audio webcast today at 8:30am EST.

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

Shares of HOOKIPA Pharma (NASDAQ:HOOK) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share were down 17.78% year over year to ($0.53), which missed the estimate of ($0.43).

News for Hookipa Pharma Inc Stock (HOOK)